The kinetics of the development of lymphokine-activated killer (LAK) cell activity, the surface phenotype, and the expression of p55 and p75 interleukin 2 receptors (IL-2R) on IL-2-activated peripheral lymphocytes have been investigated in young and old healthy humans selected according to the Senieur Protocol criteria. No difference is present between young and old healthy subjects in terms of LAK cell activity development. The proliferative capacity of lymphocytes incubated with IL-2 shows similar kinetics in young and old subjects. The mean percentages of CD56+ and CDl6+ cells reach higher levels in old than in young donors. The proportion of CD56+/CD25+ cells in culture is significantly higher in old than in young individuals. A progressive decrease of CD4+ population occurs during LAK cell development, both in young and old subjects. The proportion of CD4+ T cells in culture is lower in old than in young individuals. No age-related difference is present in the mean percentage of cells positive for p55 or p75 IL-2R at any culture time. Thus, our findings show similar kinetics of development of LAK cell activity in young and old subjects, indicating that aging per se does not represent an exclusion criterion of cancer patients from clinical trials of adoptive immunotherapy. A higher proportion of CD56+ and CDl6+ cells seems to be required in old subjects to obtain the same levels of LAK cell activity present in young age.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Quantitative investigation of a 3D bubble trapper in a high shear stress microfluidic chip using computational fluid dynamics and L*A*B* color space.
Biomed Microdevices
January 2025
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 111 Suwannabhumi Canal Rd, Bang Pla, Bang Phli District, Samut Prakan, 10540, Thailand.
Microfluidic chips often face challenges related to the formation and accumulation of air bubbles, which can hinder their performance. This study investigated a bubble trapping mechanism integrated into microfluidic chip to address this issue. Microfluidic chip design includes a high shear stress section of fluid flow that can generate up to 2.
View Article and Find Full Text PDFThe functional role of LncRNA HOXA-AS2 in multiple human cancers.
Pathol Res Pract
December 2024
Research Fellow School of Life Sciences, University of Sussex, Brighton, UK. Electronic address:
Humans have more than 270,000 lncRNAs. Among these, lncRNA HOXA-AS2 is considered a transformative gene involved in various cellular processes, including cell proliferation, apoptosis, migration, and invasion. Thus, it can be regarded as a potential tumor marker for both diagnosis and prognosis.
View Article and Find Full Text PDFA3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution.
Metabolism
December 2024
College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk, South Korea. Electronic address:
Article Synopsis
- This study focused on how the adenosine A3 receptor (A3AR) influences the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) through the regulation of immune cells, particularly pro-inflammatory Kupffer cells derived from monocytes (MoKCs).
- Researchers found that inhibiting A3AR, either through a drug called FM101 or by genetic deletion, significantly improved liver inflammation and fibrosis in model mice.
- The results suggest that targeting A3AR may offer a novel therapeutic approach for treating MASLD by inducing cell death (necroptosis) in harmful immune cells, thereby promoting a healthier liver environment.
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.
iScience
December 2024
Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, the Netherlands.
Vγ9Vδ2 T cells constitute a homogeneous effector T cell population that lyses tumors of different origin, including the prostate. We generated a bispecific T cell engager (bsTCE) to direct Vγ9Vδ2 T cells to PSMA prostate cancer (PCa) cells. The PSMA-Vδ2 bsTCE triggered healthy donor and PCa patient-derived Vγ9Vδ2 T cells to lyse PSMA PCa cell lines and patient-derived tumor cells while sparing normal prostate cells and enhanced Vγ9Vδ2 T cell antigen cross-presentation to CD8 T cells.
View Article and Find Full Text PDFExploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma.
Cancer Cell Int
November 2024
Siriraj Center of Research Excellence (SiCORE) for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Rd., 11th Floor Srisavarindhira Building, Bangkok Noi, 10700, Bangkok, Thailand.
Cholangiocarcinoma (CCA) presents a formidable therapeutic challenge due to its extensive heterogeneity and plasticity, which inevitably lead to acquired resistance to current treatments. However, recent evidence suggests that acquired drug resistance is associated with a fitness cost resulting from the myriad of acquired alterations under the selective pressure of the primary treatment. Consequently, CCA patients with acquired resistance are more susceptible to alternative therapies that are ineffective as monotherapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!